Jump to:

Product Design

PMO Analogs

Date: 31 Mar 1977
Length: 2 pages
01252110-01252111
Jump To Images
snapshot_lor 01252110-01252111

Abstract

Memo tells of Lorillard R&D efforts to find PMO analogs that could be added to cigarettes without adversely affecting taste. The PMO analogs were important because they reverse ciliastasis (paralysis of cilia which clean the respiratory tract). Experiments were done on chicken trachea tissue. 21 analogs were prepared and they were observed to have less intense and less objectionable odors and taste than PMO. They sought analogs that would be "without undesirable physiological effects such as bronchodilation." Research was done with a eye towards potentially patententing the discovered substances.

Fields

Rank
1
Author
Marmor, R.S.
Recipient
Minnemeyer, H.J.
Hypothesis
Health effects
Design changes which have measurably altered health effects of cigarette smoke, both for smokers and nonsmokers.
Measuring overall toxicity
Development of scientifically valid protocols and methods for testing the health and toxicity effects of changes in product design.
Toxicity and consumer intake
Development of scientifically valid procedures for measuring biological activity and neurological effects of nicotine and smoke constituents.
Use of additives
Modification of tobacco products through use of additives and measuring effects on dependence, behavior, and toxicity.
Keyword
Ciliatoxic
drug use
Additive
PMO analogs
Design Component
anti-ciliastatic agent
Operation/Project
PMO analogs
Subject
nicotine analogues (Technology)

Document Images

Text Control

Highlight Text:

OCR Text Alignment:

Image Control

Image Rotation:

Image Size:

Page 1: fca00e00
r MEMORANDUM TO: Dr. H. J. Minnemeyer FROM: R. S. Marmor SUBJECT: PMO Analogs History of Project _ March 31, 1977 On September 8, 1975, I proposed in a memo to you that we initiate a structure activity relationship study on PMO by preparing a number of analogs of PMO and arrang- ing to have a ciliastasis remission bioassay perforn,ad. For a commitment of relatively few man-hours, this would give us valuable information as to whether more potent PMO analogs exist, on the molecular nature of the bio- activity, and a better stance in patent protection. Over the next few months, 21 analogs were prepared. Most were observed to have less intense and more Aleas2nt odors than PMO. ~ In a memo on April 13, 1976, I listed the 21 compounds we prepared and informed you that Dr. Tong had an interest in evaluating PMO and analogs for ciliastasis remission activity by an approach different than that employed by Prof. Dalhamn. On talking further with Dr. Tong, he stated that once the system was built and operable, the testing of the analogs could be quickly performed. Dr. Schultz requested at that time that when data was available supporting activity of the analogs, we should consider expanding the scope of existing patents. On July 2, 1976, my memo to Dr. Tong stated we were ready to supply him with any samples whenever he could begin. Memos from Dr. Tong to you on October 1, 1976 and from Mr. Heck to you on November 2, 1976, indicated that the apparatus would soon be ready to begin bioassay. On March 14, 1977 in Lorillard Report #973, Dr. Tong reported on the absence of mutagenicity and high dose toxicity C for 20 of the PMO analogs. ~ ~ N FA O
Page 2: fca00e00
d Dr. H. J. Minr.emeyer - 2 - March 31, 1977 Current Status Control data for the chicken trachea ciliastasis remission experiment is presently being gathered. When this phase is complete, PMO will be studied, then testing will begin on the analogs. Further work on any active analogs would be anticipated. It is my opinion, drawn from the history of this project and the present priority level this project is being given, that there is little chance of having completed analog data in hand by the end of this year. Proposed Further Work It is premature to discuss further experiments at this time. The question now is, are there analogs of greater activity than PMO? If there are, we expect that they can be employed on cigarettes at lower dose levels such that the flavor and delivery problems will disappear. Will these more desirable analogs be without undesirable physiological effects such as bronchiodilation? Are we to ignore research on these analogs because additional biological testing would be costly and time-consuming? The trend in cigarettes to low tar-high filtration design further increases the need to investigate PMO analogs. 94, lGG[4,vrZ-- R. . Marmor RSM/lmh Xc: Dr. F. J. Schultz

Text Control

Highlight Text:

OCR Text Alignment:

Image Control

Image Rotation:

Image Size: